Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same-day restart of B/F/TAF after NNRTI discontinuation in Chinese HIV patients
ChiCTR2500098605Phase 4Not yet recruiting
- Sponsor
- National center for AlDS/STD control and prevention, China CDC
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by National center for AlDS/STD control and prevention, China CDC. Primary endpoint: HIV-RNA test results at 24 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2500098605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098605.